Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 23;9(18):4750-4754.
doi: 10.1182/bloodadvances.2025016366.

Long-term outcomes of genome-edited "universal" CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center

Daniela Guardo  1 , Avijeet Kumar Mishra  1 , Hebatalla Rashed  1 , Kimberly Gilmour  1 , Stuart Adams  1 , Danielle Pinner  1 , Martin Sauer  2 , Ajay Vora  1 , Paul Veys  1 , Vesna Pavasovic  1 , Kanchan Rao  1 , Waseem Qasim  1
Affiliations

Long-term outcomes of genome-edited "universal" CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center

Daniela Guardo et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: Great Ormond Street Hospital has previously received clinical trial support from Cellectis and Servier. W.Q. has consulted for Virocell, Wugen, and AstraZeneca. UCL Business Ltd has filed patents relating to engineered T cells.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Survival outcomes. (A) Outcomes for all children treated at Great Ormond Street Hospital with genome-edited allo-CAR19 T cells. Periods of allo-CAR19 intervention (blue), complete remission (orange), or relapse (gray) are illustrated after 2 to 10 years of follow-up. (B) EFS and OS with 40% of subjects in long-term remission above 2 years. EFS, event-free survival; OS, overall survival; P, trial UCART19 (P); S, specials license UCAR19; TT, trial TT52CAR19.
See this image and copyright information in PMC

Comment in

References

    1. Vora A, Goulden N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15(8):809–818. - PubMed
    1. Maloney KW, Devidas M, Wang C, et al. Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: results of Children's Oncology Group trial AALL0331. J Clin Oncol. 2020;38(6):602–612. - PMC - PubMed
    1. Gupta S, Rau RE, Kairalla JA, et al. Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N Engl J Med. 2025;392(9):875–891. - PMC - PubMed
    1. Litzow MR, Sun Z, Mattison RJ, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320–333. - PMC - PubMed
    1. Maude S, Laetsch T, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. - PMC - PubMed